Actinium Pharmaceuticals, Inc. — Remuneration Information 2016

Dec 8, 2016

DEFA14A 1 defa14a1216_actiniumpharma.htm DEFINITIVE ADDITIONAL MATERIALS

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Field: Rule-Page

Field: /Rule-Page

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ | Preliminary Proxy Statement | | --- | --- | | ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | | ☐ | Definitive Proxy Statement | | ☒ | Definitive Additional Materials | | ☐ | Soliciting Material under Rule 14a-12 |

Actinium Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. | | | --- | --- | --- | | ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | | | | 1. | Title of each class of securities to which transaction applies: | | | 2. | Aggregate number of securities to which transaction applies: | | | 3. | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): | | | 4. | Proposed maximum aggregate value of transaction: | | | 5. | Total fee paid: | | ☐ | Fee paid previously with preliminary materials. | | | ☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-1 1(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | | | | 1. | Amount Previously Paid: | | | 2. | Form, Schedule or Registration Statement No.: | | | 3. | Filing Party: | | | 4. | Date Filed: |

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

EXPLANATORY NOTE

Actinium Pharmaceuticals, Inc. (the “Company”) is providing shareholders with updated information relating to the Summary Compensation Table (footnote 3) on page 26 of the Company’s Proxy Statement filed on November 18, 2016.

Supplemental Information Regarding the Summary Compensation Table

All Other Compensation for Dr. Dave in 2015 totals $1,254,603, which includes restricted stock based compensation awards of $877,780, and gross-up tax payments of $376,823 made during the period.

This supplement should be considered in conjunction with the Proxy Statement.

Field: Rule-Page

Field: /Rule-Page